Effect of dissolution media and additives on the drug release from cubic phase delivery systems

Chang, Chin-Ming; Bodmeier, Roland

doi:10.1016/s0168-3659(96)01596-9

Cited by 107 publications

(82 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The susceptibility of lipid formulations to ionic strength was also reported by Chang et al (1997). The release of propranolol hydrochloride from monoglyceride matrices showed only a minor susceptibility to the ionic strength at pH 7.4 as monoglycerides are non-ionic amphiphilic molecules [30].…”

Section: In Vitro Drug Releasementioning

confidence: 76%

“…The release of propranolol hydrochloride from monoglyceride matrices showed only a minor susceptibility to the ionic strength at pH 7.4 as monoglycerides are non-ionic amphiphilic molecules [30]. showed an onset melting temperature at 120.7 °C, while stearic acid and behenic acid started melting at 68.2 °C and 74.7 °C, respectively, indicating the crystalline state of these compounds.…”

Section: In Vitro Drug Releasementioning

confidence: 99%

See 1 more Smart Citation

Prilling of fatty acids as a continuous process for the development of controlled release multiparticulate dosage forms

Vervaeck

Saerens

Geest

et al. 2013

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Section: In Vitro Drug Releasementioning

confidence: 76%

Section: In Vitro Drug Releasementioning

confidence: 99%

Prilling of fatty acids as a continuous process for the development of controlled release multiparticulate dosage forms

Vervaeck

Saerens

Geest

et al. 2013

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

“…A dialysis method was used to evaluate the in vitro release of cubosomes using a Labindia mini paddle at 50 rpm and 37 ± 0.5 °C (10,11). A cubosome formulation (equivalent to 10 mg of EFV) was placed in a dialysis bag (cellophane membrane, molecular weight cutoff 10,000-12,000, Hi-Media, India), which was then sealed at both ends.…”

Section: In Vitro Drug Release Studymentioning

confidence: 99%

“…The in vitro release of the IR suspension was done using a Labindia mini paddle at 50 rpm and 37 ± 0.5 °C. The IR suspension (equivalent to 10 mg of drug) was added with a glass syringe at the center of the dissolution vessel (10,11). At selected intervals, 1-mL aliquots were withdrawn from the release medium and replaced with the same amount of medium.…”

Section: In Vitro Drug Release Studymentioning

confidence: 99%

Optimization of a Dissolution Method in Early Development Based on IVIVC Using Small Animals: Application to a BCS Class II Drug

Deshmukh¹,

Avachat²,

Garka³

et al. 2016

Dissolution Technol.

View full text Add to dashboard Cite

The aim of the present study was to develop optimal dissolution conditions for a BCS Class II drug in early development. The model drug efavirenz was formulated in two dosage forms: a classical immediate-release suspension and modified-release cubosomes. Dissolution studies were carried out in classical and biorelevant media adapted to early development using animal models to confirm the in vitro findings. The percentage drug dissolved was calculated in all media, and the percentage absorbed was calculated from in vivo data. Level A IVIVC was investigated in all media, and the best one selected based on the highest r 2 value. Optimal dissolution media that could be used as starting points for further development are 0.5% SLS in water for cubosomes and fasted-state simulated intestinal fluid (FaSSIF) for suspensions. The predicted plasma profiles show appropriate contour, and the internal prediction error was at most 12% for the predicted parameters C max and AUC. Thus, a simple approach was used for developing IVIVC based on animal in vivo data, which can be used as a quick and simple alternative tool in early development stage depending on which dissolution method can be optimized even before human studies.

show abstract

“…Sodium deoxycholate (Na-DOC), was proposed as an alternative to polymeric matrices for developing drug carrier systems [1][2][3]. Na-DOC is a low molecular weight polymer (414.5) with advantages as low melt viscosity, potential biocompatibility, biodegradability and the absence of toxic impurities [4] (Valenta et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Gelation of Sodium-Deoxycholate: Influenced by the Presence of a CorticosteroidBetamethasone-17-Valerate

Homan¹

2017

J. Drug

View full text Add to dashboard Cite

This study was designed to evaluate the possible influences of betamethasone-17-valerate (BMV) on the gelation properties of sodium deoxycholate (Na-DOC), due to structural similarities as the monomer and the active agent. For this purpose gel formulations at two different concentrations, 0.05 and 0.1 % (w/w) were prepared and characterized by rheological and thermal analysis. The results indicated that the elastic moduli of the gels increased with increasing concentration of BMV in the system. This phenomenon was shown to be due to the modification of polymerization occurred by interactions between BMV and Na-DOC. The increment of BMV concentration in the formulation, caused a modification of the glass transition temperature (Tg) detected. Tg data pointed out a higher polymerization of Na-DOC with increasing amount of BMV. Transepidermal water loss measurements were also performed to evaluate possible skin irritation. It was observed that the degree of Na-DOC polymerization did not show any irritant effect on the skin.Overall, the results of this study clearly confirmed that incorporation of BMV into Na-DOC gel system produced a synergistic effect on product rheological characteristics, which would be beneficial for topical applications.

show abstract

Effect of dissolution media and additives on the drug release from cubic phase delivery systems

Cited by 107 publications

References 9 publications

Prilling of fatty acids as a continuous process for the development of controlled release multiparticulate dosage forms

Prilling of fatty acids as a continuous process for the development of controlled release multiparticulate dosage forms

Optimization of a Dissolution Method in Early Development Based on IVIVC Using Small Animals: Application to a BCS Class II Drug

Gelation of Sodium-Deoxycholate: Influenced by the Presence of a CorticosteroidBetamethasone-17-Valerate

Contact Info

Product

Resources

About